
To develop dosing guidelines and to evaluate the zzso of zzso in patients with liver dysfunction zzso 

Patients (N zzso zzso with varying solid tumors and liver function were zzso into four groups according to serum total zzso and zzso and were treated with escalating doses of zzso Plasma and urine were zzso for zzso of zzso and its active zzso zzso 

In the mild zzso group, zzso zzso specifically zzso and fatigue, occurred in two patients at the 600 zzso dose zzso In the moderate and severe zzso groups, the zzso dose evaluated was 300 zzso Grade 3 to 4 zzso consisted primarily of liver function test zzso zzso zzso zzso fatigue zzso and zzso zzso After the first zzso dose, the mean zzso zzso zzso areas under the plasma zzso curve from time 0 to zzso zzso were 162 zzso zzso zzso zzso 72, 182 zzso zzso and 185 zzso zzso zzso zzso zzso for normal, mild, moderate, and severe zzso groups, zzso Renal zzso of zzso was less than zzso of the total dose in all zzso 

zzso exposure (as measured by the zzso zzso did not differ between patients with normal liver function and those with zzso The zzso recommended dose of zzso for patients with mild zzso is 500 zzso zzso guidelines for patients with moderate and severe zzso remain zzso 

